ZA202309922B - Cyclic peptide-n-acetylgalactosamine (galnac) conjugates for drug delivery to liver cells - Google Patents
Cyclic peptide-n-acetylgalactosamine (galnac) conjugates for drug delivery to liver cellsInfo
- Publication number
- ZA202309922B ZA202309922B ZA2023/09922A ZA202309922A ZA202309922B ZA 202309922 B ZA202309922 B ZA 202309922B ZA 2023/09922 A ZA2023/09922 A ZA 2023/09922A ZA 202309922 A ZA202309922 A ZA 202309922A ZA 202309922 B ZA202309922 B ZA 202309922B
- Authority
- ZA
- South Africa
- Prior art keywords
- cyclic peptide
- galnac
- acetylgalactosamine
- liver cells
- conjugates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
- C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021089305 | 2021-04-23 | ||
| PCT/CN2022/088117 WO2022222986A1 (en) | 2021-04-23 | 2022-04-21 | Cyclic peptide-n-acetylgalactosamine (galnac) conjugates for drug delivery to liver cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202309922B true ZA202309922B (en) | 2025-05-28 |
Family
ID=83723528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2023/09922A ZA202309922B (en) | 2021-04-23 | 2023-10-24 | Cyclic peptide-n-acetylgalactosamine (galnac) conjugates for drug delivery to liver cells |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240218023A1 (enExample) |
| EP (1) | EP4326744A4 (enExample) |
| JP (1) | JP2024516613A (enExample) |
| KR (1) | KR20240044385A (enExample) |
| CN (1) | CN117529490A (enExample) |
| AU (1) | AU2022261265A1 (enExample) |
| IL (1) | IL307882A (enExample) |
| WO (1) | WO2022222986A1 (enExample) |
| ZA (1) | ZA202309922B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024117938A1 (ru) * | 2022-11-30 | 2024-06-06 | Общество с ограниченной ответственностью "СИСТЕМА-БИОТЕХ" | Способы получения биоконъюгатов для печень-специфической направленной модуляции протеома |
| CN118804921A (zh) * | 2023-01-17 | 2024-10-18 | 云合智药（苏州）生物科技有限公司 | 缀合物、配体单元及其用途 |
| EP4745237A1 (en) * | 2023-07-14 | 2026-05-20 | Yun Ho Bio Co., Ltd | ARNI AGENT TO INHIBIT THE EXPRESSION AND USE OF KETOHEXOKINASE |
| WO2026159213A1 (en) * | 2025-01-23 | 2026-07-30 | Astrazeneca Ab | Targeted lipid nanoparticles |
| CN120040554B (zh) * | 2025-04-25 | 2025-07-18 | 云合智药（苏州）生物科技有限公司 | 环肽类肝靶向化合物、药物组合物及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4657721B2 (ja) * | 2002-09-19 | 2011-03-23 | センター ナショナル デ ラ レシェルシェ サイエンティフィック（シーエヌアールエス） | 新規な誘導システムの合成及び特徴付け、並びに標的細胞への治療対象分子のベクター化 |
| FR2959993B1 (fr) * | 2010-05-17 | 2014-10-17 | Commissariat Energie Atomique | Nouveaux composes cyclodecapeptides et leurs applications |
| EP2624848A2 (en) * | 2010-10-04 | 2013-08-14 | Centre National De La Recherche Scientifique CNRS | Compositions comprising multivalent synthetic ligands of surface nucleolin and glycosaminoglycans |
| US8501930B2 (en) * | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
| CA3134610A1 (en) * | 2018-04-09 | 2019-10-17 | Yale University | Bifunctional small molecules to target the selective degradation of circulating proteins |
| WO2019217682A1 (en) * | 2018-05-09 | 2019-11-14 | Ohio State Innovation Foundation | Cyclic cell-penetrating peptides with one or more hydrophobic residues |
| WO2020181130A2 (en) * | 2019-03-05 | 2020-09-10 | MiRagen Therapeutics, Inc. | Polynucleotide conjugates and uses thereof |
| EP4100064A1 (en) * | 2020-02-07 | 2022-12-14 | Novartis AG | Targeted plasma protein degradation |
-
2022
- 2022-04-21 CN CN202280043909.8A patent/CN117529490A/zh active Pending
- 2022-04-21 AU AU2022261265A patent/AU2022261265A1/en active Pending
- 2022-04-21 US US18/556,040 patent/US20240218023A1/en active Pending
- 2022-04-21 KR KR1020237040193A patent/KR20240044385A/ko active Pending
- 2022-04-21 EP EP22791092.4A patent/EP4326744A4/en active Pending
- 2022-04-21 WO PCT/CN2022/088117 patent/WO2022222986A1/en not_active Ceased
- 2022-04-21 JP JP2023564508A patent/JP2024516613A/ja active Pending
- 2022-04-21 IL IL307882A patent/IL307882A/en unknown
-
2023
- 2023-10-24 ZA ZA2023/09922A patent/ZA202309922B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4326744A1 (en) | 2024-02-28 |
| WO2022222986A1 (en) | 2022-10-27 |
| AU2022261265A1 (en) | 2023-11-09 |
| EP4326744A4 (en) | 2026-05-20 |
| JP2024516613A (ja) | 2024-04-16 |
| KR20240044385A (ko) | 2024-04-04 |
| IL307882A (en) | 2023-12-01 |
| CN117529490A (zh) | 2024-02-06 |
| US20240218023A1 (en) | 2024-07-04 |
| AU2022261265A9 (en) | 2023-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021550692A1 (en) | Conjugation linkers containing 2,3-diaminosuccinyl group | |
| NZ589086A (en) | Human serum albumin (HSA) linkers and conjugates thereof | |
| Pasut et al. | Polymer–drug conjugation, recent achievements and general strategies | |
| Pan et al. | Synthesis of Long‐Circulating, Backbone Degradable HPMA Copolymer–Doxorubicin Conjugates and Evaluation of Molecular‐Weight‐Dependent Antitumor Efficacy | |
| MX2022008629A (es) | Nanoparticulas lipidicas para la administracion de farmacos in vivo, y usos de las mismas. | |
| DE602007011901D1 (de) | Ptiden und zellpenetrierenden peptiden gekoppelt a | |
| UA91512C2 (ru) | Коньюгати олигомеров инсулина, их композиция (варианты) и применение | |
| EP2266590A3 (en) | Active agent delivery sytems and methods for protecting and administering active agents | |
| WO2004084950A3 (en) | Cell targeting methods and compositions | |
| MXPA05005330A (es) | Composiciones y formulaciones de gastrina, y metodos de uso y preparacion. | |
| EP1542723A4 (en) | Highly reactive and soluble crosslinkers and their use in the preparation of conjugates for the targeted delivery of small-molecule drugs | |
| TR200101751T2 (tr) | Poliol-IFN-beta konjugatları | |
| WO2009001364A3 (en) | Targeting conjugates comprising active agents encapsulated in cyclodextrin-containing polymers | |
| KR20120104513A (ko) | 부갑상선 호르몬 수준을 감소시키기 위한 치료제 | |
| WO2002062396A3 (en) | Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents using polymer conjugates | |
| WO2011097384A2 (en) | Tumor targeted delivery of immunomodulators by nanoplymers | |
| WO2010065950A3 (en) | Albumin binding peptide-mediated disease targeting | |
| EP4237012A1 (en) | Fap-activated serum extended half-life therapeutic conjugates | |
| Kato et al. | Targeted delivery of peptides, proteins, and genes by receptor-mediated endocytosis | |
| MX2022009819A (es) | Moleculas de union al antigeno anti-grupo de diferenciacion 137 (cd137) para usarse en el tratamiento contra el cancer. | |
| MY157187A (en) | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance | |
| EP4237011A1 (en) | Enzyme activated serum extended half-life therapeutic conjugates | |
| CA2723823A1 (en) | Conjugates for the treatment of mesothelioma | |
| PL373795A1 (en) | Thymosin alpha 1 peptide/polymer conjugates | |
| ES2607986T3 (es) | Agentes terapéuticos para regular el fósforo en suero |